BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beijing Biotech anti-CD19 CAR-T readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Beijing Biotech anti-CD19 CAR-T\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07523542-5559@assetmemo.bio
DTSTAMP:20261121T010014Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Beijing Biotech anti-CD19 CAR-T: Phase 1/2 readout est. (NCT0752354
 2)
DESCRIPTION:Beijing Biotech anti-CD19 CAR-T\, phase 1/2\, Systemic Lupus Er
 ythematosus.\nStudy: SELECT-SLE: Biomarker-Guided CAR-T Target Selection f
 or Refractory Lupus\nEstimated primary completion: 14 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/beijing-biotech-anti-cd19-car
 -t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7523542
URL:https://assetmemo.bio/drug/beijing-biotech-anti-cd19-car-t#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
